Evidence map›Paper›PMID 29220404›Full record

ArticlePloS one2017

PyMT-Maclow: A novel, inducible, murine model for determining the role of CD68 positive cells in breast tumor development.

Robin M H Rumney, Seth B Coffelt, Terence A Neale, Sandeep Dhayade, Gillian M Tozer, Gaynor Miller

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Robin M H RumneyDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.
Seth B CoffeltDepartment of Infection & Immunity, University of Sheffield, Sheffield, United Kingdom.
Terence A NealeDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.
Sandeep DhayadeCancer Research UK Beatson Institute, Glasgow, United Kingdom.
Gillian M TozerDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.
Gaynor MillerDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.ORCID http://orcid.org/0000-0003-4527-3814
University of Sheffield · GBCancer Research UK Scotland Institute · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD68+ tumor-associated macrophages (TAMs) are pro-tumorigenic, pro-angiogenic and are associated with decreased survival rates in patients with cancer, including breast cancer. Non-specific models of macrophage ablation reduce the number of TAMs and limit the development of mammary tumors. However, the lack of specificity and side effects associated with these models compromise their reliability. We hypothesized that specific and controlled macrophage depletion would provide precise data on the effects of reducing TAM numbers on tumor development. In this study, the MacLow mouse model of doxycycline-inducible and selective CD68+ macrophage depletion was crossed with the murine mammary tumor virus (MMTV)-Polyoma virus middle T antigen (PyMT) mouse model of spontaneous ductal breast adenocarcinoma to generate the PyMT-MacLow line. In doxycycline-treated PyMT-MacLow mice, macrophage numbers were decreased in areas surrounding tumors by 43%. Reducing the number of macrophages by this level delayed tumor progression, generated less proliferative tumors, decreased the vascularization of carcinomas and down-regulated the expression of many pro-angiogenic genes. These results demonstrate that depleting CD68+ macrophages in an inducible and selective manner delays the development of mammary tumors and that the PyMT-MacLow model is a useful and unique tool for studying the role of TAMs in breast cancer.

Indexed as

Disease Models, AnimalAnimalsAntigens, CDAntigens, Differentiation, MyelomonocyticBreast NeoplasmsCD68 MoleculeDoxycyclineFemaleHumansMacrophagesMiceAntigens, CDAntigens, Differentiation, MyelomonocyticCD68 antigen, humanCD68 MoleculeDoxycycline

Identifiers

PMID29220404
PMCPMC5722323
OpenAlexW2773348969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.